Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

ALXN2023 - CONCORD (Antibody-Mediated Rejection after Kidney Transplant) - Clinical Trial

Email for Information

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called ALXN2030 (the study drug) is a safe and effective option for people diagnosed with antibody-mediated rejection (AMR) of a transplanted kidney.

¿Cuál es la Condición que se está estudiando?

Antibody-Mediated Rejection (AMR) of a Kidney After Transplant

¿Quién puede participar en el Estudio?

Adultos de 18 a 75 años que:

Are diagnosed with active or chronic active AMR
Are vaccinated against meningococcal infection, pneumonia, and influenza

For more information, contact the study team at hanajoy.porter@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment to either:

Obtener el fármaco del estudio; O
Administre un placebo (sustancia inactiva que no contiene ningún medicamento)

The study drug or placebo is given as an intravenous (IV) infusion every 3 months. Participation in the study will last for about 3 years.

Detalles del Estudio

Título Completo

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation

Investigador Principal